Chargement en cours...
HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice variant survivin-2B can be recognized by CD8(+) cytotoxic T-cells. The identification of an HLA-A24 epitope is critical for survivin-based immunotherapy as HLA-24 is the most frequent HLA allele in Asia. C...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2006
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1564416/ https://ncbi.nlm.nih.gov/pubmed/16948867 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-4-38 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|